NIAID TETRAMER FACILITY
NIAID 四聚体设施
基本信息
- 批准号:7958122
- 负责人:
- 金额:$ 5.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-01 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAllelesAnimalsArtsAustraliaAutoimmunityCanadaCenters for Disease Control and Prevention (U.S.)ClinicalClinical ResearchCommunicable DiseasesCommunitiesComputer Retrieval of Information on Scientific Projects DatabaseContractsDepartment of DefenseDoctor of PhilosophyEuropeFoundationsFundingGrantHumanImmune responseInstitutesInstitutionIsraelMalignant NeoplasmsMethodologyMusNational Institute of Allergy and Infectious DiseaseNonprofit OrganizationsOrgan TransplantationPrimatesProductionQualifyingQuality ControlReagentResearchResearch PersonnelResearch SupportResourcesSourceSpecimenT-LymphocyteUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesVirginiacostdesignnonhuman primatepre-clinicalprogramsrepositoryvaccine evaluation
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The National Institute of Allergy and Infectious Diseases (NIAID) supports reagent programs and repositories that provide centralized resources for the research community. These facilities support research by providing reliable sources of quality assured materials, specimens, or experimental animals at reasonable cost to qualified investigators. The NIAID Tetramer Facility, established at Emory University in 1998 under the direction of John Altman, Ph.D., serves the scientific community as a centralized source of quality-controlled tetramer reagents for basic, preclinical, and clinical research. The NIAID Division of AIDS oversees the Facility, which is contracted by the AIDS Research and Reference Reagent Program with subcontracts to McKesson BioServices and Virginia Mason.
The Facility has provided tetramer reagents, comprising human, murine, and non-human primate MHC alleles to researchers at non-profit organizations both in the U.S. and abroad, including investigators supported by ten NIH Institutes, the Food and Drug Administration, the Department of Defense, the Centers for Disease Control and Prevention, and private non-profit U.S. foundations, as well as to researchers in Europe, Australia, Israel, and Canada; has produced tetramers applicable to a wide range of T cell studies, including research on AIDS and other infectious diseases, cancer, organ transplantation, autoimmunity, clinical vaccine evaluation, and basic studies on T cells and immune responses; and has developed standardized methodology for tetramer usage and evaluated new advances in tetramer design and production to assure that the Facility's reagents reflect state-of-the-art capabilities.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
美国国家过敏症和传染病研究所(NIAID)支持为研究界提供集中资源的试剂项目和资料库。这些设施通过以合理的价格向合格的研究人员提供可靠的有质量保证的材料、标本或实验动物来源来支持研究。NIAID四聚体设施于1998年在约翰·奥特曼博士的指导下在埃默里大学建立,作为基础、临床前和临床研究的质量控制四聚体试剂的集中来源,为科学界服务。NIAID艾滋病部门监督该设施,该设施由艾滋病研究和参考试剂计划承包,分包给McKesson BioServices和弗吉尼亚·梅森。
该机构已经向美国和国外非营利性组织的研究人员提供了包括人类、小鼠和非人类灵长类MHC等位基因的四聚体试剂,包括得到美国国立卫生研究院、食品和药物管理局、国防部、疾病控制和预防中心和美国私人非营利性基金会支持的研究人员,以及欧洲、澳大利亚、以色列和加拿大的研究人员;生产了适用于广泛T细胞研究的四聚体,包括艾滋病和其他传染病、癌症、器官移植、自身免疫、临床疫苗评估和T细胞和免疫反应的基础研究;并开发了四聚体使用的标准化方法,并评估了四聚体设计和生产方面的新进展,以确保该设施的试剂反映最先进的能力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John David Altman其他文献
John David Altman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John David Altman', 18)}}的其他基金
INFLUENZA PATHOGENESIS AND IMMUNOLOGY RESEARCH CENTER:T CELL RESPONSES
流感发病机制和免疫学研究中心:T 细胞反应
- 批准号:
8357561 - 财政年份:2011
- 资助金额:
$ 5.67万 - 项目类别:
Enhancing the Immunogenicity and Utility of MVA-Based AIDS Vaccines
增强基于 MVA 的艾滋病疫苗的免疫原性和实用性
- 批准号:
8075652 - 财政年份:2010
- 资助金额:
$ 5.67万 - 项目类别:
THE ROLE OF LEUKOCYTE SEQUESTRATION IN THE CONTROL OF VIRALINFECTIONS
白细胞隔离在控制病毒感染中的作用
- 批准号:
8172445 - 财政年份:2010
- 资助金额:
$ 5.67万 - 项目类别:
Enhancing the Immunogenicity and Utility of MVA-Based AIDS Vaccines
增强基于 MVA 的艾滋病疫苗的免疫原性和实用性
- 批准号:
7927768 - 财政年份:2010
- 资助金额:
$ 5.67万 - 项目类别:
CONTROLLING HIV/SIV WITH DRUGS THAT MANIPULATE LYMPHOCYTE TRAFFICKING
使用控制淋巴细胞贩运的药物控制 HIV/SIV
- 批准号:
8172439 - 财政年份:2010
- 资助金额:
$ 5.67万 - 项目类别:
OPTIMIZE THE IMMUNOGENICITY OF MVA-BASED AIDS VACCINES
优化基于 MVA 的艾滋病疫苗的免疫原性
- 批准号:
7958169 - 财政年份:2009
- 资助金额:
$ 5.67万 - 项目类别:
THE ROLE OF LEUKOCYTE SEQUESTRATION IN THE CONTROL OF VIRALINFECTIONS
白细胞隔离在控制病毒感染中的作用
- 批准号:
7958273 - 财政年份:2009
- 资助金额:
$ 5.67万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 5.67万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 5.67万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 5.67万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 5.67万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 5.67万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 5.67万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 5.67万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 5.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 5.67万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 5.67万 - 项目类别: